東誠藥業(002675.SZ)與北京大學、昆明植物所簽署共同開發新靶點創新藥物合同
格隆匯4月20日丨東誠藥業(002675.SZ)公佈,為進一步提升公司的核心競爭力,公司與北京大學、中國科學院昆明植物研究所三方於近期簽署了《技術轉讓合同》和《技術開發(合作)合同》,三方共同參與研究開發新靶點抗血栓化學創新藥DCP118(“DCP118”)。開發完成後,公司將獲得DCP118在全球的專利、臨牀開發與註冊、生產和市場銷售的獨家權利。
該產品為新靶點抗血栓候選新藥,通過相關專利方法制備的新分子實體化合物,臨牀適應症為治療和/或預防血栓形成性疾病。
公司通過與北京大學、中國科學院昆明植物研究所進行技術合作開發全新靶點創新藥物,開拓肝素、低分子肝素類抗血栓藥物之外的新領域,符合公司豐富抗血栓藥物產品管線的戰略定位,對公司的創新發展有積極推動作用,有助於提升公司未來的市場競爭力。此次簽署技術開發合同對公司短期經營業績不會構成重大影響,但長期來看有助於公司增加產品的經營種類,豐富產品管線,拓寬收入和利潤來源,符合公司戰略發展的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.